Keywords: USA, FDA, Teva, Sanofi-Aventis, Lovenox, BioSantem Skin cancer vaccine, Melanoma
US FDA issues action letter for Teva’s generic Lovenox; grants orphan status for BioSante vaccine
Article | 26 January 2011
Global generic drug major Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced yesterday that it has received correspondence from the US ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
